The Present and FutureJACC Review Topic of the WeekInflammation, Immunity, and Infection in Atherothrombosis: JACC Review Topic of the Week
Central Illustration
Key Words
Abbreviations and Acronyms
Cited by (0)
Dr. Libby was supported by grants from the National Heart, Lung, and Blood Institute (NHLBI) (HL080472) and the RRM Charitable Fund. Dr. Loscalzo was supported by National Institutes of Health (NIH) grants HL119145, HG007690, GM107618, and HL061795, and the American Heart Association grant Scaling the Computation of Predicting Drug Protein Interactions. Dr. Farkouh has received NIHLBI grant support (U01HL28606). Dr. Hsue has received grant support from the National Institute of Allergy and Infectious Diseases (K24AI112393) and the NIH (R01HL125034). Dr. Amar has received grant support from the NHLBI (R01HL076801) and the NIH (R01DE014079). Dr. Libby’s laboratory has received funding from Novartis; he is an unpaid consultant to Amgen, AstraZeneca, Esperion Therapeutics, Ionis Pharmaceuticals, Sanofi-Regeneron, and XBiotech, Inc.; and a member of the scientific advisory board for Corvidia Therapeutics, Olatec Therapeutics, and MedImmune. Dr. Ridker has received research grant support from Novartis, Kowa, Pfizer, and the NHLBI; has served as a consultant for Novartis, Corvidia, Inflazome, and Pfizer; and is listed as a co-inventor on patents held by the Brigham and Women’s Hospital that relate to the use of inflammatory biomarkers in cardiovascular disease and diabetes that have been licensed to AstraZeneca and Seimens. Dr. Farkouh has received research support from Amgen. Dr. Hsue has received grant support from Pfizer; and has received honoraria from Gilead. Dr. Hasan works for the NHLBI/NIH, but any opinions, findings, and conclusions expressed in this review are those of the author and do not reflect the views of the NHLBI or the NIH. Dr. Fuster has reported that he has no relationships relevant to the contents of this paper to disclose.